Vol. 5 No. 12 (2025)
Reimbursement Recommendations

Tofersen (Qalsody)

decorative image of the issue cover

Published December 10, 2025

Key Messages

  • Canada’s Drug Agency (CDA-AMC) recommends that Qalsody be reimbursed by public drug plans for the treatment of adults with amyotrophic lateral sclerosis (ALS) if certain conditions are met.
  • Qalsody should only be covered for adults (aged 18 years or older) who have ALS associated with a confirmed SOD1 gene mutation, verified through genetic testing, and who exhibit muscle weakness attributable to ALS.
  • Qalsody should only be reimbursed when it is prescribed and monitored by an ALS specialist such as a neurologist or physiatrist within a multidisciplinary clinic, and the cost of Qalsody is reduced.